Services

Toxicology

Pharmacology

Animal Model Development

Medical Device Testing

In Vitro Screening

Custom Assay Development

Vivarium Rental

Histology

Therapeutic Areas

Oncology

Immunology & Inflammation

Neurology / CNS

Cardiovascular

Dermatology & Wound Healing

Metabolism

Gastroenterology

Hepatology

Pulmonology

Infectious Diseases & Sepsis

Musculoskeletal

Nephrology & Urology

Species

Non-human Primates

Dogs

Minipigs / Pigs

Rabbits

Mice

Rats

Sheep

Guinea Pigs

Hamsters

Other Species

Capabilities

GLP / IND-Enabling Studies

Small and Large Animal Housing

Bioanalytical Platforms

About

News

Contact

Careers

Request a Quote

Logo
☰
  • Services ⌄
    • Toxicology
    • Pharmacology
    • Animal Model Development
    • Medical Device Testing
    • In Vitro Screening
    • Custom Assay Development
    • Vivarium Rental
    • Histology
  • Therapeutic Areas ⌄
    • Oncology
    • Immunology & Inflammation
    • Neurology / CNS
    • Cardiovascular
    • Dermatology & Wound Healing
    • Metabolism
    • Gastroenterology
    • Hepatology
    • Pulmonology
    • Infectious Diseases & Sepsis
    • Musculoskeletal
    • Nephrology & Urology
  • Species ⌄
    • Non-human Primates
    • Dogs
    • Minipigs / Pigs
    • Rabbits
    • Mice
    • Rats
    • Sheep
    • Guinea Pigs
    • Hamsters
    • Other Species
  • Capabilities ⌄
    • GLP / IND-Enabling Studies
    • Small and Large Animal Housing
    • Bioanalytical Platforms
  • About ⌄
    • News
  • Contact ⌄
    • Careers
    • Request a Quote

Legislative Update — Week of April 29, 2024

  • Post author:PacConAdmin
  • Post published:April 29, 2024
  • Post category:Uncategorized

As the second session of the 118th Congress begins, FDAnews will track important pending legislation, that has been acted on since Oct. 1, 2023 to keep you updated on laws…

Continue ReadingLegislative Update — Week of April 29, 2024

Brain Biopsy Needle That Could Leave Behind Steel Debris Sees Class I Recall

  • Post author:PacConAdmin
  • Post published:April 29, 2024
  • Post category:Uncategorized

A biopsy needle designed for use with a system that helps locate and diagnose brain tumors has been recalled by the manufacturer, Elekta Instrument AB, and is now deemed a…

Continue ReadingBrain Biopsy Needle That Could Leave Behind Steel Debris Sees Class I Recall

Quick Notes: Four Class I Device Recalls — April 26, 2024

  • Post author:PacConAdmin
  • Post published:April 26, 2024
  • Post category:Uncategorized

In this edition of Quick Notes, the FDA has elevated four device recalls to Class I, including an infusion pump that has caused six injuries and one death, two PCB-leaching…

Continue ReadingQuick Notes: Four Class I Device Recalls — April 26, 2024

European Parliament Greenlights Second Deadline Extension for IVD Makers

  • Post author:PacConAdmin
  • Post published:April 26, 2024
  • Post category:Uncategorized

This week, the European Parliament adopted the European Commission’s (EC) proposal to grant more time for companies to come into compliance with 2022’s In Vitro Diagnostic Medical Devices Regulation (IVDR).…

Continue ReadingEuropean Parliament Greenlights Second Deadline Extension for IVD Makers

Marketing of Problem-Laden Syringes Earns Cardinal Health FDA Warning Letter

  • Post author:PacConAdmin
  • Post published:April 26, 2024
  • Post category:Uncategorized

Cardinal Health received an FDA Warning Letter because the company is marketing Monoject convenience kits that include 3 mL, 10 mL, and 20 mL piston syringes and control syringes made…

Continue ReadingMarketing of Problem-Laden Syringes Earns Cardinal Health FDA Warning Letter

Regulatory Update — Week of April 22, 2024

  • Post author:PacConAdmin
  • Post published:April 26, 2024
  • Post category:Uncategorized

This week, the FDA announced a Medical Devices Advisory Committee meeting, availability of a report on postmarketing performance of drug firms, revised draft guidance on biologic promotional labeling and advertising,…

Continue ReadingRegulatory Update — Week of April 22, 2024

Draft Guidance Assists in Writing NDA, ANDA Drug Component List to Speed Approval

  • Post author:PacConAdmin
  • Post published:April 26, 2024
  • Post category:Uncategorized

Minimizing the number of assessment cycles and communications to get to approval is the goal of an FDA draft guidance on the composition statements needed for NDAs and ANDAs. Source:…

Continue ReadingDraft Guidance Assists in Writing NDA, ANDA Drug Component List to Speed Approval

Quick Notes: Drug Approvals — April 25, 2024

  • Post author:PacConAdmin
  • Post published:April 25, 2024
  • Post category:Uncategorized

In this edition of Quick Notes, the FDA finally OKs a 40-year-old European mainstay antibiotic for uncomplicated UTIs, an immunotherapy for bladder cancer, a generic form of Narcan nasal spray,…

Continue ReadingQuick Notes: Drug Approvals — April 25, 2024

Sanders, Senate HELP Committee Investigating Novo Nordisk Price Gouging in US

  • Post author:PacConAdmin
  • Post published:April 25, 2024
  • Post category:Uncategorized

A Senate committee has demanded answers from Danish pharma Novo Nordisk on what it labels “astronomically” high prices for the company’s Ozempic/Wegovy (semaglutide) diabetes/weight loss drugs, while a report points…

Continue ReadingSanders, Senate HELP Committee Investigating Novo Nordisk Price Gouging in US

FDA OCP Seeks Public Input on Drug Development Clinical Pharmacology Programs

  • Post author:PacConAdmin
  • Post published:April 25, 2024
  • Post category:Uncategorized

The FDA is soliciting input from interested parties on policy topics the CDER Office of Clinical Pharmacology (OCP) could develop and implement to support drug development programs. Source: Drug Industry…

Continue ReadingFDA OCP Seeks Public Input on Drug Development Clinical Pharmacology Programs
  • Go to the previous page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • …
  • 143
  • Go to the next page

Stay Connected

Keep up with the latest news & insights.

Contact Us

Phone:
+1 858-605-5882
Fax:
+1 858-605-5916
Email:
info@biolegacyresearch.com
Mail:
6042 Cornerstone Court W
Suite E
San Diego, CA 92121
Social::
© 2025 BioLegacy Research. All rights reserved.
BioLegacy research is a PharmaLegacy Laboratories company